News for Oncobiologics, Inc. (ONS)

Published at

Jun 13, 2024 11:50 AM

by seekingalpha.com

neutral

neutral

Outlook Therapeutics: Speculative Buy With High Stakes In Anti-VEGF Market (NASDAQ:OTLK)

Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. See why I rate OTLK stock as a speculative buy.

OTLK ONS

Read more →
Published at

Mar 21, 2024 5:00 PM

by zacks.com

neutral

neutral

All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy

Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ONS

Read more →
Published at

May 25, 2023 3:55 PM

by zacks.com

neutral

neutral

Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

ONS

Read more →
Published at

Oct 22, 2022 7:58 AM

by etfdailynews.com

mixed

mixed

Qiagen (NYSE:QGEN) and Outlook Therapeutics (NASDAQ:OTLK) Financial Survey

Read Qiagen (NYSE:QGEN) and Outlook Therapeutics (NASDAQ:OTLK) Financial Survey at ETF Daily News

SSMXY SSMXF QIAN.MX QIA.DE QGEN OTLK IPCALAB.NS IPCALAB.BO 6869N.MX 6869.T ONS

Read more →
Published at

May 23, 2022 4:18 AM

by etfdailynews.com

positive

positive

Head-To-Head Review: Achilles Therapeutics (NASDAQ:ACHL) and Outlook Therapeutics (NASDAQ:OTLK)

Read Head-To-Head Review: Achilles Therapeutics (NASDAQ:ACHL) and Outlook Therapeutics (NASDAQ:OTLK) at ETF Daily News

OTLK ONS IPCALAB.NS IPCALAB.BO ACHL

Read more →
Published at

Dec 5, 2021 8:04 AM

by etfdailynews.com

positive

positive

Zacks Investment Research Upgrades Outlook Therapeutics (NASDAQ:OTLK) to Hold

Zacks Investment Research upgraded shares of Outlook Therapeutics (NASDAQ:OTLK) from a sell rating to a hold rating in a report released on Wednesday morning, Zacks.com reports. According to Zacks, “Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet […]

OTLK ONS

Read more →

News for Oncobiologics, Inc. (ONS)

Outlook Therapeutics: Speculative Buy With High Stakes In Anti-VEGF Market (NASDAQ:OTLK)

All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy

Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?

Qiagen (NYSE:QGEN) and Outlook Therapeutics (NASDAQ:OTLK) Financial Survey

Head-To-Head Review: Achilles Therapeutics (NASDAQ:ACHL) and Outlook Therapeutics (NASDAQ:OTLK)

Zacks Investment Research Upgrades Outlook Therapeutics (NASDAQ:OTLK) to Hold